![](/images/graphics-bg.png)
Comparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.pt
المؤلفون المشاركون
Bernardes, Miguel
C. Romão, Vasco
Santos, Maria José
Polido-Pereira, Joaquim
Duarte, Cátia
Nero, Patrícia
Miguel, Cláudia
Costa, José António
Pimentel-Santos, Fernando M.
Barcelos, Filipe
Costa, Lúcia
Melo Gomes, José António
Pereira da Silva, José Alberto
Branco, Jaime Cunha
Canas da Silva, José
Pereira da Silva, José António
Canhão, Helena
Fonseca, Joao Eurico
المصدر
العدد
المجلد 2015، العدد 2015 (31 ديسمبر/كانون الأول 2015)، ص ص. 1-13، 13ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2015-04-27
دولة النشر
مصر
عدد الصفحات
13
التخصصات الرئيسية
الملخص EN
Objectives.
To compare the effectiveness of TNF inhibitors (TNFi) and tocilizumab in rheumatoid arthritis (RA) treatment, according to different response criteria.
Methods.
We included RA patients registered in the Rheumatic Diseases Portuguese Register treated with TNFi or tocilizumab for at least 6 months, between January 2008 and July 2013.
We assessed remission/low disease activity (LDA) at 6 months according to DAS28, CDAI, and SDAI, as well as Boolean ACR/EULAR remission and EULAR response rate, adjusting for measured confounders.
Results.
Tocilizumab-treated patients ( n = 95 ) presented higher baseline disease activity and were less frequently naïve to biologics compared to TNFi users ( n = 429 ).
Multivariate logistic regression analysis including the propensity score for receiving tocilizumab showed that patients treated with tocilizumab were more likely to achieve remission or LDA according to DAS28 (OR = 11.0/6.2, 95% CI 5.6–21.6/3.2–12.0), CDAI (OR = 2.8/2.6, 95% CI 1.2–6.5/1.3–5.5), or SDAI (OR = 3.6/2.5, 95% CI 1.5–8.7/1.1–5.5), as well as a good EULAR response (OR = 6.4, 95% CI 3.4–12.0).
However, both groups did not differ in Boolean remission (OR = 1.9, 95% CI 0.8–4.8) or good/moderate EULAR response (OR = 1.8, 95% CI 0.8–4.5).
Conclusions.
Compared with TNFi, tocilizumab was associated with greater likelihood of achieving DAS28, CDAI, and SDAI remission/LDA and EULAR good response.
Boolean remission and EULAR good/moderate response did not differ significantly between groups.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
C. Romão, Vasco& Santos, Maria José& Polido-Pereira, Joaquim& Duarte, Cátia& Nero, Patrícia& Miguel, Cláudia…[et al.]. 2015. Comparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.pt. BioMed Research International،Vol. 2015, no. 2015, pp.1-13.
https://search.emarefa.net/detail/BIM-1054857
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
C. Romão, Vasco…[et al.]. Comparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.pt. BioMed Research International No. 2015 (2015), pp.1-13.
https://search.emarefa.net/detail/BIM-1054857
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
C. Romão, Vasco& Santos, Maria José& Polido-Pereira, Joaquim& Duarte, Cátia& Nero, Patrícia& Miguel, Cláudia…[et al.]. Comparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.pt. BioMed Research International. 2015. Vol. 2015, no. 2015, pp.1-13.
https://search.emarefa.net/detail/BIM-1054857
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1054857
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)